Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Availability:

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 20 of 20
MONDAY PRESS CONFERENCE
WELCOME AND OVERVIEW OF CROI 2017
Susan P. Buchbinder
CROI Chair and University of California, San Francisco, CA, USA
Judith Currier
CROI Vice Chair and University of California, Los Angeles, CA, USA
Richard Koup
CROI Vice Chair and National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
from CROI 2017 on February 13, 2017 3:00 PM-3:45 PM
MONDAY PRESS CONFERENCE
DISCUSSION OF ORAL ABSTRACT SESSION 4 – NEW HIV DRUGS, FORMULATIONS, COMBINATIONS, AND RESISTANCE
CHAIR
Joseph Eron
University of North Carolina, Chapel Hill, NC, USA
OA4: DISCOVERY OF NOVEL POTENT HIV CAPSID INHIBITORS WITH LONG-ACTING POTENTIAL
Winston Tse
Gilead Scis, Inc, Foster City, CA, USA
OA4: RANDOMIZED TRIAL OF BICTEGRAVIR OR DOLUTEGRAVIR WITH FTC/TAF FOR INITIAL HIV THERAPY
Paul Sax
Brigham and Women's Hosp, Boston, MA, USA
OA4: PREVALENCE AND IMPACT OF PRETREATMENT DRUG RESISTANCE IN THE ANRS 12249 TASP TRIAL
Anne Derache
Africa Hlth Rsr Inst, Mtubatuba, South Africa
OA4: PHASE III SWORD 1&2: SWITCH TO DTG+RPV MAINTAINS VIROLOGIC SUPPRESSION THROUGH 48 WKS
Josep M. Llibre
Univ Hosp Germans Trias, Badalona, Barcelona, Spain
from CROI 2017 on February 13, 2017 3:00 PM-3:45 PM
TUESDAY PRESS CONFERENCE
DISCUSSION OF ORAL ABSTRACT SESSION 2 – CRITICAL ISSUES IN WOMEN'S HEALTH, MTCT, AND HIV TREATMENT IN CHILDREN
CHAIR
Elaine Abrams
Columbia University, New York, NY, USA
OA2: RANDOMIZED TRIAL OF LEEP VS CRYOTHERAPY TO TREAT CIN2/3 IN HIV-INFECTED WOMEN
Sharon Greene
Univ of Washington, Seattle, WA, USA
OA2: INTEGRATION OF POSTNATAL SERVICES IMPROVES MCH AND ART OUTCOMES: A RANDOMISED TRIAL
Landon Myer
Univ of Cape Town, Cape Town, South Africa
OA2: ADVERSE BIRTH OUTCOMES DIFFER BY ART REGIMEN FROM CONCEPTION IN BOTSWANA
Rebecca Zash
Beth Israel Deaconess Med Cntr, Boston, MA, USA
OA2: EFFECT OF POINT-OF-CARE TESTING ON ANTIRETROVIRAL-THERAPY INITIATION RATES IN INFANTS
Ilesh Jani
Instituto Nacional de Saude, Maputo, Mozambique
OA2: TREATMENT OF ACUTE HIV INFECTION IN NEONATES
Louise Kuhn
Columbia Univ, New York, NY, USA
from CROI 2017 on February 14, 2017 12:15 PM-1:15 PM
TUESDAY PRESS CONFERENCE
DISCUSSION OF ORAL ABSTRACT SESSION 3 – HIDING IN PLAIN SIGHT: DISCOVERING THE UNDIAGNOSED AND UNDERTREATED HIV EPIDEMIC
CHAIR
Kevin M. De Cock
Centers for Disease Control and Prevention, Nairobi, Kenya
OA3: HIV INCIDENCE, PREVALENCE, AND UNDIAGNOSED INFECTIONS IN MEN WHO HAVE SEX WITH MEN
Sonia Singh
CDC, Atlanta, GA, USA
OA3: VIRAL-LOAD DYNAMICS AMONG PERSONS WITH DIAGNOSED HIV: UNITED STATES, 2014
Nicole Crepaz
CDC, Atlanta, GA, USA
OA3: COMBINATION HIV PREVENTION AND HIV INCIDENCE IN RAKAI, UGANDA
Mary Grabowski
The Johns Hopkins Univ, Baltimore, MD, USA
from CROI 2017 on February 14, 2017 12:15 PM-1:15 PM
TUESDAY PRESS CONFERENCE
DISCUSSION OF POSTER SESSION – EMERGING VIRUSES: ZIKA VIRUS AND THEMED DISCUSSION 17 – EMERGING VIRUSES: THE ZIKA VIRUS
CHAIR
David Thomas
Johns Hopkins School of Medicine, Baltimore, MD, USA
TD17: ZIKA VIRUS PERSISTENCE IN BODY FLUIDS
Gabriela Paz-Bailey
CDC, Atlanta, GA, USA
TD17: NEUROLOGIC CONSEQUENCES OF POSTNATAL ZIKA VIRUS INFECTION IN INFANTS
Maud Mavigner
Emory Univ, Atlanta, GA, USA
TD17: ZIKA VIRUS PROTECTION BY A SINGLE LOW-DOSE NUCLEOSIDE-MODIFIED MRNA VACCINATION
Michael Hogan
Univ of Pennsylvania, Philadelphia, PA, USA
from CROI 2017 on February 14, 2017 12:15 PM-1:15 PM
WEDNESDAY PRESS CONFERENCE
DISCUSSION OF ORAL ABSTRACT SESSION 7 – TB AND OTHER OPPORTUNISTIC INFECTIONS
CHAIR
Constance A Benson
University of California at San Diego, San Diego, CA, USA
OA7: A MULTICENTER DIAGNOSTIC ACCURACY STUDY OF THE XPERT ULTRA FOR TUBERCULOSIS DIAGNOSIS
Timothy Rodwell
FIND, Geneva, Switzerland
OA7: SIX-MONTH IPT REDUCES MORTALITY INDEPENDENTLY OF ART IN AFRICAN ADULTS WITH HIGH CD4
Anani Badje
INSERM, Bordeaux, France
OA7: RANDOMIZED CONTROLLED TRIAL OF PREDNISONE FOR PREVENTION OF PARADOXICAL TB-IRIS
Graeme Meintjes
Univ of Cape Town, Cape Town, South Africa
from CROI 2017 on February 15, 2017 12:15 PM-1:15 PM
WEDNESDAY PRESS CONFERENCE
DISCUSSION OF ORAL ABSTRACT SESSION 8 – COMMON BEDFELLOWS: PREP, STIS, AND THE MICROBIOME
CHAIR
Wafaa El-Sadr
ICAP at Columbia University, New York, NY, USA
OA8: RESISTANCE EMERGENCE IN MACAQUES ADMINISTERED CABOTEGRAVIR LA DURING ACUTE INFECTION
Gerardo Garcia-Lerma
CDC, Atlanta, GA, USA
OA8: DAILY ORAL PREP IS EFFECTIVE AMONG WOMEN WITH ABNORMAL VAGINAL MICROBIOTA
Renee Heffron
Univ of Washington, Seattle, WA, USA
OA8: IMPACT OF VAGINAL MICROBIOTA ON GENITAL TISSUE AND PLASMA CONCENTRATIONS OF TENOFOVIR
Sharon Hillier
Univ of Pittsburgh, Pittsburgh, PA, USA
OA8: ON DEMAND POST EXPOSURE PROPHYLAXIS WITH DOXYCYCLINE FOR MSM ENROLLED IN A PREP TRIAL
Jean-Michel Molina
St. Louis, Hosp, Paris, France
from CROI 2017 on February 15, 2017 12:15 PM-1:15 PM
WEDNESDAY PRESS CONFERENCE
DISCUSSION OF POSTER SESSION 4 – HIV AND SUBSTANCE USE: DOUBLE TROUBLE AND THEMED DISCUSSION SESSION 14 – HIV AND SUBSTANCE USE: DOUBLE TROUBLE
CHAIR
Susan P. Buchbinder
CROI Chair and University of California, San Francisco, CA, USA
TD14: "HOOKED ON PAINKILLERS" PRIOR TO FIRST INJECTION AMONG PWID IN 16 U.S. CITIES
Dita Broz
CDC, Atlanta, GA, USA
TD14: CHANGES IN PRESCRIPTION OPIOID, METH, AND COCAINE USE AMONG MSM IN 20 U.S. CITIES
Brooke Hoots
CDC, Atlanta, GA, USA
TD14: INCREASING METHAMPHETAMINE USE AMONG NON-MSM WHO INJECT DRUGS IN KING COUNTY, WA
Sara Glick
Univ of Washington, Seattle, WA, USA
from CROI 2017 on February 15, 2017 12:15 PM-1:15 PM
THURSDAY PRESS CONFERENCE
DISCUSSION OF ORAL ABSTRACT SESSION 9 – HEPATITIS C: PROBLEMS AND PROGRESS
CHAIR
David Thomas
Johns Hopkins School of Medicine, Baltimore, MD, USA
OA9: MODELING HIV-HCV EPIDEMIOLOGY IN THE DAA ERA: THE ROAD TO ERADICATION
Victor Virlogeux
INSERM, Lyon, France
OA9: SUBSTANTIAL DECLINE IN ACUTE HCV INFECTIONS AMONG DUTCH HIV+ MSM AFTER DAA ROLL OUT
Bart Rijnders
Erasmus Univ Med Cntr, Rotterdam, Netherlands
from CROI 2017 on February 16, 2017 12:15 PM-1:15 PM
THURSDAY PRESS CONFERENCE
DISCUSSION OF ORAL ABSTRACT SESSION 12 – INFLAMATION AND AGE-RELATED COMPLICATIONS
CHAIR
Peter Hunt
University of California, San Francisco, CA, USA
OA12: IL-1&BETA; INHIBITION SIGNIFICANTLY REDUCES ATHEROSCLEROTIC INFLAMMATION IN TREATED HIV
Priscilla Hsue
Univ of California San Francisco, San Francisco, CA, USA
OA12: ASSOCIATION BETWEEN CARDIOVASCULAR DISEASE & CONTEMPORARILY USED PROTEASE INHIBITORS
Lene Ryom
CHIP, Copenhagen, Denmark
OA12: CESSATION OF CIGARETTE SMOKING AND THE IMPACT ON CANCER INCIDENCE IN THE D:A:D STUDY
Leah Shepherd
Univ Coll London, London, UK
from CROI 2017 on February 16, 2017 12:15 PM-1:15 PM
THURSDAY PRESS CONFERENCE
DISCUSSION OF ORAL ABSTRACT SESSION 11 – HIV PERSISTENCE AND REACTIVATION AND POSTER SESSION 4 – HIV PERSISTENCE: SEND IN THE CLONES
CHAIR
Peter Hunt
University of California, San Francisco, CA, USA
OA11: VIRAL CONTROL INDUCED BY HIVCONSV VACCINES & ROMIDEPSIN IN EARLY TREATED INDIVIDUALS
Beatriz Mothe
IrsiCaixa AIDS Rsr Inst, Badalona, Spain
OA11: NO EVIDENCE OF ONGOING HIV REPLICATION AFTER 7 YEARS ON ART
Mary Kearney
NCI, Frederick, MD, USA
PS4: RESURGENCE OF HIV-1 FOUNDER VIRUSES FOLLOWING ANTIRETROVIRAL TREATMENT INTERRUPTION
Morgane Rolland
US Military HIV Rsr Prog, Silver Spring, MD, USA
from CROI 2017 on February 16, 2017 12:15 PM-1:15 PM
Monday Press Conference
Welcome and Overview of CROI 2016
Julie M. Overbaugh
CROI Chair and Fred Hutchinson Cancer Research Center, Seattle, WA, United States
Susan P. Buchbinder
CROI Vice Chair and University of California, San Francisco, CA, United States
Judith Currier
CROI Vice Chair and University of California, Los Angeles, CA, United States
from CROI 2016 on February 22, 2016 2:00 PM-3:00 PM
Monday Press Conference
Discussion of Special Session – Ebola: One Year Later
Chair
Kevin M. De Cock
CDC, Nairobi, Kenya
SS - EBOLA: Sequelae of Ebola Virus Disease in Surviving Patients in Guinea: Postebogui Cohort
Eric Delaporte
UMI 233-IRD/U1175-INSERM/Montpellier University, Montpellier, France
SS - EBOLA: Dynamics of Ebola Virus Clearance in Semen in Guinea
Daouda Sissoko
INSERM U897, Bordeaux, France
from CROI 2016 on February 22, 2016 2:00 PM-3:00 PM
Monday Press Conference
Discussion of Oral Abstract Session 9 – Expanding the Toolbox for Prevention
Chair
Wafaa El-Sadr
ICAP at Columbia University, New York, NY, United States
OA9: A Phase III Trial of the Dapivirine Vaginal Ring for HIV-1 Prevention in Women
Jared M. Baeten
University of Washington, Seattle, WA, United States
OA9: Safety and Efficacy of Dapivirine Vaginal Ring for HIV-1 Prevention in African Women
Annalene Nel
International Partnership for Microbicides, Paarl, South Africa
from CROI 2016 on February 22, 2016 2:00 PM-3:00 PM
Tuesday Press Conference
Discussion of Oral Abstract Session 1 – SIV and HIV Pathogenesis and Oral Abstract Session 5 – Strategies for Testing and Linkage to Care: Are We Closing the Gap?
Chair
John Coffin
Tufts University, Medford, MA, United States
Chair
Susan P. Buchbinder
University of California, San Francisco, CA, United States
OA1: HIV-1 Laboratory Contagion During Recombination Procedures With Defective Constructs
Claudia Alteri
University of Rome Tor Vergata, Rome, Italy
OA5: Estimating the Lifetime Risk of a Diagnosis of HIV Infection in the United States
Kristen Hess
US Centers for Disease Control and Prevention, Atlanta, GA, United States
OA5: Increased HIV Viral Suppression Among US Adults Receiving Medical Care, 2009-2013
Heather Bradley
US Centers for Disease Control and Prevention, Atlanta, GA, United States
OA5: Narrowing the Gap in Life Expectancy for HIV+ Compared With HIV- Individuals
Julia L. Marcus
Kaiser Permanente Northern California, Oakland, CA, United States
OA5: Perception of Infectiousness in HIV-Infected Persons After Initiating ART: ACTG A5257
Raphael J. Landovitz
David Geffen School of Medicine, University of California, Los Angeles, CA, United States
from CROI 2016 on February 23, 2016 12:30 PM-1:30 PM
Tuesday Press Conference
Discussion of Oral Abstract Session 3 – Prevention and Treatment of Pediatric HIV Infections
Chair
Elaine J. Abrams
Columbia University, New York, NY, United States
OA3: Impact of Option B+ on ART Uptake and Retention in Swaziland: A Stepped-Wedge Trial
Harriet Nuwagaba-Biribonwoha
ICAP, Columbia University Mailman School of Public Health, New York, NY, United States
OA3: National HIV Transmission in 4-12 Week Olds in Malawi's PMTCT Option B+ Program
Sundeep Gupta
CDC, Harare, Zimbabwe
OA3: Impact of Maternal Tenofovir Use on HIV-Exposed Newborn Bone Mineral
George K. Siberry
Eunice Kennedy Shriver NICHD, Bethesda, MD, United States
OA3: Similar Mortality With Cotrimoxazole vs Placebo in HIV-Exposed Uninfected Children
Roger L. Shapiro
Harvard School of Public Health, Boston, MA, United States
from CROI 2016 on February 23, 2016 12:30 PM-1:30 PM
Wednesday Press Conference
Discussion of Oral Abstract Session 10 – Getting to 90-90-90 and Symposium Session 5 – Reaching 90-90-90 and Beyond: Challenges and Innovations
Chair
Diane Havlir
University of California, San Francisco, CA, United States
OA10: Botswana Is Close to Meeting UNAIDS 2020 Goals of 90-90-90 Coverage
Tendani Gaolathe
Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana
OA10: Streamlining Antiretroviral Therapy Uptake: A Stepped-Wedge Cluster Randomized Trial
Gideon Amanyire
Makerere University College of Health Sciences, Kampala, Uganda
OA10: HIV Mortality by Care Cascade Stage and Implications for Universal ART Eligibility
Jeffrey Eaton
Imperial College London, London, United Kingdom
SS5: Missing But in Action: Where Are the Men?
Helen Ayles
London School of Hygiene & Tropical Medicine, London, United Kingdom
SS5: Innovations in Antiretroviral Therapy Delivery
Anna Grimsrud
International AIDS Society, Cape Town, South Africa
from CROI 2016 on February 24, 2016 12:30 PM-1:30 PM
Wednesday Press Conference
Discussion of Oral Abstract Session 9 – Expanding the Toolbox for Prevention and Themed Discussion Session 12 – It's Complicated: Renal Function and STIs in PrEP Users and Poster Abstract Session 3 – Predictors of PrEP Coverage and Uptake
Chair
Sharon L. Hillier
University of Pittsburgh School of Medicine, Magee-Womens Hospital, PA, United States
OA9: ÉCLAIR: Phase 2A Safety and PK Study of Cabotegravir LA in HIV Uninfected Men
Martin Markowitz
Aaron Diamond AIDS Research Center, New York, NY, United States
TD12: Higher Cumulative TFV/FTC Levels in PrEP Associated With Decline in Renal Function
Monica Gandhi
University of California San Francisco, San Francisco, CA, United States
TD12: Changes in Renal Function Associated With TDF/FTC PrEP Use in the US Demo Project
Albert Y. Liu
San Francisco Dept of Public Health, San Francisco, CA, United States
TD12: STI Data From Community-Based PrEP Implementation Suggest Changes to CDC Guidelines
Sarit A. Golub
Hunter College, City University of New York, NY, United States
PAS3: HPTN 073: PrEP Uptake and Use by Black Men Who Have Sex With Men in 3 US Cities
Darrell P. Wheeler
State University of New York at Albany, Albany, NY, United States
from CROI 2016 on February 24, 2016 12:30 PM-1:30 PM
Thursday Press Conference
Discussion of Plenary Session 6 – The Evolving Epidemiology of HIV Infection in Persons Who Inject Drugs: Indiana 2015 and Oral Abstract Session 13 – HCV: Curing the Patient but Not the Population
Chair
Harold W. Jaffe
US Centers for Disease Control and Prevention, Atlanta, GA, United States
PL6: The Evolving Epidemiology of HIV Infection in Persons Who Inject Drugs: Indiana 2015
John Brooks
US Centers for Disease Control and Prevention, Atlanta, GA, United States
OA13: Networks of HCV Transmissions Among Persons Who Inject Drugs: Indiana, 2015
Sumathi Ramachandran
US Centers for Disease Control and Prevention, Atlanta, GA, United States
from CROI 2016 on February 25, 2016 12:30 PM-1:30 PM
Thursday Press Conference
Discussion of Oral Abstract Session 14 – Tuberculosis and Other Opportunistic Infections/Cancer Prevention: Hits and Misses
Chair
Richard Chaisson
Johns Hopkins University School of Medicine and Bloomberg School of Public Health, Baltimore, MD, United States
OA14: Empirical TB Treatment in Advanced HIV Disease: Results of the TB Fast Track Trial
Alison Grant
London School of Hygiene & Tropical Medicine, London, United Kingdom
OA14: Acceptability of Large-Scale Household-Based TB Screening: HPTN 071 (PopART)
Comfort R. Phiri
ZAMBART, Lusaka, Zambia
OA14: HIV-Associated XDR TB Is Transmitted in Households and Hospitals in South Africa
Sara C. Auld
Emory University, Atlanta, GA, United States
OA14: Pre-ART Cryptococcal Antigen Titer Associated With Preemptive Fluconazole Failure
Bozena M. Morawski
University of Minnesota, Minneapolis, MN, United States
from CROI 2016 on February 25, 2016 12:30 PM-1:30 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 20 of 20